This study, involving patients with early rheumatoidarthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.
This study found that methotrexate, when administered according to current recommendations, effectively manages rheumatoidarthritis for many patients in Poland, although regular monitoring is necessary due to possible adverse effects.
1 citations
,
June 2013 in “Annals of the Rheumatic Diseases”
This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.
13 citations
,
January 1999 in “Postgraduate Medicine”
This article reviews new drug combinations and unique agents for rheumatoidarthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoidarthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
A 27-year-old woman with androgenic alopecia is losing hair despite using oral minoxidil and spironolactone, and is considering dutasteride. She is exploring causes like stress and medication side effects, planning tests, and considering treatment changes.
An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.
a JAK inhibitor for alopecia areata and other autoimmune conditions
What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata?Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.